[ 3 / biz / cgl / ck / diy / fa / ic / jp / lit / sci / vr / vt ] [ index / top / reports ] [ become a patron ] [ status ]

/biz/ - Business & Finance

Search:


View post   

>> No.17135835 [View]
File: 9 KB, 228x221, 92C2BE6A-CBB0-4955-ABEE-B323E9DFB80E.jpg [View same] [iqdb] [saucenao] [google]
17135835

>>17135792
...your brain went to cuckoldry before thinking you and your wife might have children?

>> No.16583759 [View]
File: 9 KB, 228x221, B184F16A-F2C8-4443-9C4E-0BEDB5385D56.jpg [View same] [iqdb] [saucenao] [google]
16583759

>>16583684
>Democrats just killed their hopes for 2020
Economy did that.
Black swan event tanks the economy, trump loses. Simple as.

Everything Dems and reps do in the meantime is about donations, and making sure a base is fired up in case there is a black swan.

Trump and aoc are both pumping donor money into each others campaigns, mutually beneficial relationship.

>> No.16520834 [View]
File: 9 KB, 228x221, 8D85F206-28BC-4595-A4C6-5A0F339761CD.jpg [View same] [iqdb] [saucenao] [google]
16520834

>>16520788
You just said you’re only here because you were rejected everywhere else!
VERY RUDE
>>16520792
>Tolkien is real
>cigarettes are good for you
>inverted humans

>finland doesn’t exist
Hehe

>> No.16512884 [View]
File: 9 KB, 228x221, F4F81D1B-1E0E-4083-8F8B-D841B9624483.jpg [View same] [iqdb] [saucenao] [google]
16512884

>>16512835
Ah yes, always resort to denial at first. Assume it’s bullshit fud. Do no research.

>02:51 PM EST, 12/09/2019 (MT Newswires) -- Galectin Therapeutics (GALT), a developer of therapeutics that target galectin proteins, on Monday reported mixed results from its cirrhosis clinical trial on belapectin.
>The company said the second mid-stage study of 162 patients with Nash (nonalcoholic steatohepatitis), cirrhosis, and portal hypertension, one year of biweekly infusion of belapectin was safe but not associated with significant reduction in hepatic venous pressure gradient or fibrosis, compared with placebo.
>The study highlighted, however, that in a subgroup analysis of patients without esophageal varices, a dose of belapectin reduced HVPG and development of varices. That subgroup analysis suggested that there could be benefits from belapectin in patients with Nash cirrhosis without esophageal varices.
>Last week, Galectin said it is planning an adaptively designed late-stage trial of belapectin in Nash cirrhosis patients.
>Shares fell 3% in intraday trading on Monday.
>Price: 2.91, Change: -0.08, Percent Change: -2.68

Navigation
View posts[+24][+48][+96]